APLS
HealthcareApellis Pharmaceuticals, Inc. · Biotechnology · $5B
What is Apellis Pharmaceuticals, Inc.?
Apellis Pharmaceuticals is a commercial-stage biopharmaceutical company targeting the complement system — a key driver of autoimmune and inflammatory diseases. It is headquartered in Waltham, Massachusetts.
Apellis develops and commercializes therapies that inhibit the complement system, a branch of the immune system implicated in a range of serious diseases. Its lead asset, pegcetacoplan, is approved and in active trials across conditions including geographic atrophy, paroxysmal nocturnal hemoglobinuria, and several rare kidney and blood disorders.
Apellis was founded in 2017 and is based in Waltham, US.
- EMPAVELI (systemic pegcetacoplan) for hematologic conditions
- SYFOVRE (intravitreal pegcetacoplan) for geographic atrophy in age-related macular degeneration
- APL-2006, a bispecific C3 and VEGF inhibitor in development
- APL-1030, a C3 inhibitor targeting neurodegenerative diseases
Is APLS a Good Stock to Buy?
UQS Score rates APLS as Below Average overall.
Growth stands out as the strongest pillar, reflecting the commercial launch trajectory of its approved products and a pipeline spanning multiple rare disease indications. Moat and Risk both register as Neutral, suggesting a company with some competitive positioning but meaningful uncertainties typical of clinical-stage expansion.
Quality is rated Weak, pointing to profitability challenges common in early commercial-stage biotechs. Valuation is Elevated, meaning the current price reflects significant future expectations.
See the exact pillar breakdown and full financial metrics by signing up for a UQS Pro account. Sign up free →
Past performance does not guarantee future results. UQS Score is based on fundamental data and is not a buy/sell recommendation.
Does APLS pay dividends?
No — Apellis Pharmaceuticals, Inc. does not currently pay a dividend.
Apellis does not pay a dividend. As a commercial-stage biopharmaceutical company still investing heavily in clinical development and commercialization, capital is directed toward pipeline expansion and product launches rather than shareholder distributions.
When does APLS report earnings?
Apellis Pharmaceuticals reports earnings on a quarterly cadence, typical for US-listed equities.
Revenue growth has been driven by the commercial ramp of its approved products, though the company continues to operate at a loss as it funds ongoing trials and commercial infrastructure. Progress across multiple indications will be a key focus for investors each quarter.
For the most recent quarter's results, see Apellis Pharmaceuticals' investor relations page.
APLS Price History
-27.3% over 5Y
Monthly close, adjusted for stock splits and dividend reinvestment.
What if I invested in Apellis Pharmaceuticals, Inc.?
Based on Apellis Pharmaceuticals, Inc.'s historical closing prices, adjusted for stock splits and dividend reinvestment. Past performance does not guarantee future results. This is for informational purposes only and is not financial advice.
Frequently Asked Questions
What does Apellis Pharmaceuticals do?
Apellis Pharmaceuticals discovers and commercializes therapies that inhibit the complement system, targeting autoimmune and inflammatory diseases. Its approved products address geographic atrophy and paroxysmal nocturnal hemoglobinuria, with a pipeline spanning rare kidney, blood, and neurological conditions.
Does APLS pay dividends?
No, APLS does not currently pay a dividend. The company reinvests available capital into clinical development and the commercialization of its approved therapies, which is typical for commercial-stage biotechs with active pipelines.
When does APLS report earnings?
Apellis reports on a standard quarterly schedule. For confirmed dates and the most recent results, visit the investor relations section of the company's official website.
Is APLS a good stock to buy?
UQS Score rates APLS as Below Average overall. Growth is the standout pillar, but Weak Quality and Elevated Valuation introduce meaningful risk. Investors should weigh the pipeline opportunity against the current profitability profile before drawing conclusions.
Is APLS overvalued?
UQS Score flags APLS's Valuation pillar as Elevated, meaning the market is pricing in substantial future success. Whether that premium is justified depends on execution across its approved products and pipeline milestones.
Is APLS a long-term quality indicator?
On the UQS long-term quality framework, APLS scores Below Average. Growth is a positive signal, but Weak Quality and Elevated Valuation suggest the company needs to demonstrate improving fundamentals before it registers as a high-quality compounder.
What sector does APLS belong to?
Apellis Pharmaceuticals operates in the Healthcare sector, specifically within the biopharmaceutical industry. It focuses on rare and serious diseases driven by complement system dysregulation.
What is APLS's market cap bracket?
APLS is classified as a mid-cap stock, reflecting its commercial-stage status with approved products generating revenue, while still carrying the risk profile of a company with an active and expanding clinical pipeline.
Unlock Full APLS Analysis
Sign in to unlock the detailed analysis behind the UQS Score.
- ✓View the complete UQS pillar breakdown across Quality, Growth, Moat, Risk, and Valuation
- ✓Access detailed financial metrics and trend data
- ✓Compare APLS against sector peers on a standardized scoring framework
- ✓Get the full analyst-style view available to Pro members
Pro Analysis
APLS — Score History
| Date | UQS | Quality | Moat | Growth | Risk | Value | Change |
|---|---|---|---|---|---|---|---|
| May 16, 2026 | 50.6 | 65.3 | 43.0 | 62.4 | 63.4 | 10.3 | -0.1 |
| May 14, 2026 | 50.7 | 65.3 | 43.0 | 62.7 | 63.4 | 10.3 | -3.3 |
| May 11, 2026 | 54.0 | 65.3 | 43.0 | 62.7 | 85.9 | 10.3 | +13.4 |
| Apr 18, 2026 | 40.6 | 32.9 | 43.0 | 62.4 | 59.2 | 1.7 | -0.1 |
| Apr 9, 2026 | 40.7 | 32.9 | 43.0 | 62.4 | 59.2 | 2.4 | +0.1 |
| Apr 2, 2026 | 40.6 | 32.9 | 43.0 | 61.7 | 59.2 | 2.4 | — |
APLS — Pillar Breakdown
Quality
— 65.3/100 (25%)Apellis Pharmaceuticals, Inc. shows solid profitability with healthy returns on capital and reasonable margins.
How effectively capital is deployed to generate returns.
Profitability relative to shareholders' equity.
Ability to convert revenue into operating profit.
Bottom-line profit as a share of revenue.
Asset productivity — how much gross profit each dollar of assets generates.
Free cash flow relative to market value.
Growth
— 62.4/100 (20%)Apellis Pharmaceuticals, Inc. demonstrates healthy growth trends across revenue and earnings.
Revenue trajectory over the last twelve months.
Compound annual revenue growth rate over 3 years.
Year-over-year earnings per share growth.
Analyst consensus for future revenue growth.
Risk
— 63.4/100 (15%)Apellis Pharmaceuticals, Inc. maintains a reasonable risk profile with manageable debt levels.
Debt levels relative to earnings capacity.
Total debt relative to shareholder equity.
Short-term liquidity — ability to pay near-term obligations.
Earnings capacity relative to interest payments.
Valuation
— 10.3/100 (15%)Apellis Pharmaceuticals, Inc. appears expensively valued relative to its fundamentals and growth prospects.
Inverse of forward P/E — higher yield means cheaper stock.
How many years of FCF the market cap represents.
Enterprise value multiple relative to sector median.
Moat
— 43/100 (25%)Apellis Pharmaceuticals, Inc. possesses some competitive advantages but faces meaningful competition. The Moat pillar evaluates competitive advantages across five dimensions: Switching Costs, Network Effects, Cost Advantage, Intangible Assets, and Scale & Ecosystem. Sign in to customize moat ratings for APLS.
Score Composition
Financial Data
More Stock Analysis
How is the APLS UQS Score Calculated?
The UQS (Unified Quality Score) for Apellis Pharmaceuticals, Inc. is calculated using a proprietary 6-pillar framework with 29 financial metrics. Each pillar evaluates a different dimension on a 0–100 scale, then combines into a single weighted score. Scoring thresholds are calibrated per sector. Momentum is an optional Pro toggle — without it, you get the 5-pillar / 25-metric core shown below.
Quality (25%) measures profitability and capital efficiency — ROIC, ROE, margins, GP/Assets, and FCF Yield.
Moat (25%) assesses Apellis Pharmaceuticals, Inc.'s competitive advantages across switching costs, network effects, cost advantages, intangible assets, and ecosystem scale.
Growth (20%) tracks revenue trajectory and earnings momentum, combining historical results with analyst forward estimates.
Risk (15%) is inversely scored — lower leverage and strong balance sheet health result in higher scores.
Valuation (15%) measures whether Apellis Pharmaceuticals, Inc. is fairly priced using earnings yield, price-to-FCF, PEG ratio, and EV/EBITDA relative to sector peers.
Six investor-inspired presets are available, each with different pillar weights: Balanced, Buffett, Munger, Lynch, Cathie Wood, and Graham. The public score shown here uses the Balanced preset. Learn more in our FAQ.